FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130915160> ?p ?o ?g. }

• W2130915160 endingPage "2254" @default.
• W2130915160 startingPage "2243" @default.
• W2130915160 abstract "Altered expression and activity of cyclin-dependent kinase (CDK) and tropomyosin receptor kinase (TRK) families are observed in a wide variety of tumors. In those malignancies with aberrant CDK activation, the retinoblastoma protein (pRb) pathway is deregulated, leading to uncontrolled cell proliferation. Constitutive activation of TRKs is instead linked to cancer cell survival and dissemination. Here, we show that the novel small-molecule PHA-848125, a potent dual inhibitor of CDKs and TRKs, possesses significant antitumor activity. The compound inhibits cell proliferation of a wide panel of tumoral cell lines with submicromolar IC(50). PHA-848125-treated cells show cell cycle arrest in G(1) and reduced DNA synthesis, accompanied by inhibition of pRb phosphorylation and modulation of other CDK-dependent markers. The compound additionally inhibits phosphorylation of TRKA and its substrates in cells, which functionally express this receptor. Following oral administration, PHA-848125 has significant antitumor activity in various human xenografts and carcinogen-induced tumors as well as in disseminated primary leukemia models, with plasma concentrations in rodents in the same range as those found active in inhibiting cancer cell proliferation. Mechanism of action was also confirmed in vivo as assessed in tumor biopsies from treated mice. These results show that the dual CDK-TRK inhibitor PHA-848125 has the potential for being a novel and efficacious targeted drug for cancer treatment." @default.
• W2130915160 created "2016-06-24" @default.
• W2130915160 creator A5001666583 @default.
• W2130915160 creator A5002876711 @default.
• W2130915160 creator A5005794932 @default.
• W2130915160 creator A5007214576 @default.
• W2130915160 creator A5008691829 @default.
• W2130915160 creator A5018214424 @default.
• W2130915160 creator A5021457170 @default.
• W2130915160 creator A5023227792 @default.
• W2130915160 creator A5026821481 @default.
• W2130915160 creator A5031466676 @default.
• W2130915160 creator A5042529900 @default.
• W2130915160 creator A5044377393 @default.
• W2130915160 creator A5049504158 @default.
• W2130915160 creator A5051084648 @default.
• W2130915160 creator A5072610596 @default.
• W2130915160 creator A5080881030 @default.
• W2130915160 creator A5083934929 @default.
• W2130915160 creator A5085619076 @default.
• W2130915160 creator A5088929149 @default.
• W2130915160 date "2010-08-01" @default.
• W2130915160 modified "2023-09-27" @default.
• W2130915160 title "Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy" @default.
• W2130915160 cites W152943885 @default.
• W2130915160 cites W1885155229 @default.
• W2130915160 cites W1965049479 @default.
• W2130915160 cites W1967625949 @default.
• W2130915160 cites W1982624212 @default.
• W2130915160 cites W1990750564 @default.
• W2130915160 cites W1992509138 @default.
• W2130915160 cites W2000590884 @default.
• W2130915160 cites W2004970079 @default.
• W2130915160 cites W2006547874 @default.
• W2130915160 cites W2007618242 @default.
• W2130915160 cites W2015728503 @default.
• W2130915160 cites W2016410910 @default.
• W2130915160 cites W2019607817 @default.
• W2130915160 cites W2020330574 @default.
• W2130915160 cites W2036520923 @default.
• W2130915160 cites W2046024621 @default.
• W2130915160 cites W2056447951 @default.
• W2130915160 cites W2074642772 @default.
• W2130915160 cites W2075223448 @default.
• W2130915160 cites W2075750487 @default.
• W2130915160 cites W2076614364 @default.
• W2130915160 cites W2078246081 @default.
• W2130915160 cites W2082973537 @default.
• W2130915160 cites W2085113511 @default.
• W2130915160 cites W2088120691 @default.
• W2130915160 cites W2098203835 @default.
• W2130915160 cites W2098752829 @default.
• W2130915160 cites W2103501749 @default.
• W2130915160 cites W2103998574 @default.
• W2130915160 cites W2106123852 @default.
• W2130915160 cites W2110795584 @default.
• W2130915160 cites W2113604152 @default.
• W2130915160 cites W2118010975 @default.
• W2130915160 cites W2120350411 @default.
• W2130915160 cites W2125170260 @default.
• W2130915160 cites W2125294721 @default.
• W2130915160 cites W2130027655 @default.
• W2130915160 cites W2130147203 @default.
• W2130915160 cites W2132066963 @default.
• W2130915160 cites W2152107294 @default.
• W2130915160 cites W2153389501 @default.
• W2130915160 cites W4250161016 @default.
• W2130915160 doi "https://doi.org/10.1158/1535-7163.mct-10-0190" @default.
• W2130915160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20682657" @default.
• W2130915160 hasPublicationYear "2010" @default.
• W2130915160 type Work @default.
• W2130915160 sameAs 2130915160 @default.
• W2130915160 citedByCount "49" @default.
• W2130915160 countsByYear W21309151602012 @default.
• W2130915160 countsByYear W21309151602013 @default.
• W2130915160 countsByYear W21309151602014 @default.
• W2130915160 countsByYear W21309151602015 @default.
• W2130915160 countsByYear W21309151602016 @default.
• W2130915160 countsByYear W21309151602017 @default.
• W2130915160 countsByYear W21309151602018 @default.
• W2130915160 countsByYear W21309151602019 @default.
• W2130915160 countsByYear W21309151602020 @default.
• W2130915160 countsByYear W21309151602021 @default.
• W2130915160 countsByYear W21309151602022 @default.
• W2130915160 countsByYear W21309151602023 @default.
• W2130915160 crossrefType "journal-article" @default.
• W2130915160 hasAuthorship W2130915160A5001666583 @default.
• W2130915160 hasAuthorship W2130915160A5002876711 @default.
• W2130915160 hasAuthorship W2130915160A5005794932 @default.
• W2130915160 hasAuthorship W2130915160A5007214576 @default.
• W2130915160 hasAuthorship W2130915160A5008691829 @default.
• W2130915160 hasAuthorship W2130915160A5018214424 @default.
• W2130915160 hasAuthorship W2130915160A5021457170 @default.
• W2130915160 hasAuthorship W2130915160A5023227792 @default.
• W2130915160 hasAuthorship W2130915160A5026821481 @default.
• W2130915160 hasAuthorship W2130915160A5031466676 @default.
• W2130915160 hasAuthorship W2130915160A5042529900 @default.
• W2130915160 hasAuthorship W2130915160A5044377393 @default.

• next